Juvenescence investing $43.2 million in AgeX

Juvenescence will purchase, in a single transaction, 14.4 million shares of AgeX Therapeutics from BioTime for $43.2 million. 50% of the purchase price will be paid to BioTime in cash and the remaining 50% will be a 2-year convertible/redeemable note with an annual interest rate of 7%, payable at maturity.

Juvenescence is developing multiple therapeutics focused on improving and extending human lifespans. The Juvenescence team comprises proven and seasoned experts in drug development, strategy, structure, commercialization and finance. From its outset, Juvenescence has staked out a major footprint in AI, and specifically in machine and deep learning through its part ownership of Insilico Medicine and through its ownership in NetraPharma and Juvenescence AI. Access to these two AI engines from our joint ventures will assist our efforts in drug discovery, as well as in optimizing human trials of the therapeutics we develop. Our company’s pipeline consists of pre-clinical candidates that have been joint ventured with leading research institutions and associated scientist inventors. In addition, we are partners with established companies such as Age X, where our role is to provide finance, development expertise and to help guide products with management towards commercialization.

AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. The company’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The products under development include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based therapies in the preclinical stage of development comprised of young regenerative cells formulated in the company’s proprietary HyStem® matrix designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which the Company plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, the company, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. In addition, the company, through its ESI BIO division, markets Cytiva®, comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.

12 thoughts on “Juvenescence investing $43.2 million in AgeX”

  1. Revel is the next company to be spun out (off Yale’s work on breaking glucosepane crosslinks). Should happen in the next few months. Will target high blood pressure due to inelastic arteries and wrinkles. Also in the past week Repair Biotechnologies Inc (founded by Reason, author of the Fightaging blog) has been funded by the Grapeseed Bio fund: “Founded by Reason and Bill Cherman in April 2018, Repair Biotechnologies will use these new funds to expand its foundational gene therapy development work with the addition of a recombinant protein engineering program, as it proceeds towards proof of concept results in animal models.” Repair Bio will use a FOXN1 gene therapy to attempt to rejuvenate the thymus, and probably an engineered bacterial enzyme to try and remove oxidised cholesterol from foam cells in the arteries.

    Reply
  2. Revel is the next company to be spun out (off Yale’s work on breaking glucosepane crosslinks). Should happen in the next few months. Will target high blood pressure due to inelastic arteries and wrinkles.Also in the past week Repair Biotechnologies Inc (founded by Reason author of the Fightaging blog) has been funded by the Grapeseed Bio fund:Founded by Reason and Bill Cherman in April 2018″ Repair Biotechnologies will use these new funds to expand its foundational gene therapy development work with the addition of a recombinant protein engineering program” as it proceeds towards proof of concept results in animal models.””Repair Bio will use a FOXN1 gene therapy to attempt to rejuvenate the thymus”””” and probably an engineered bacterial enzyme to try and remove oxidised cholesterol from foam cells in the arteries.”””

    Reply
  3. Used to have a bottle of one of the older crosslink breakers. It was a failure in tests for lowering blood pressure, but did a fantastic job cleaning your teeth; Decay bacteria rely on those same cross links to anchor themselves to teeth! A drop on the old tooth brush was as good as a professional cleaning. The life extension research really seems to be heating up. Actuarially, I’ve got maybe another 20 years if I take care of myself. Some of this stuff might even be out of trials and available in time for me!

    Reply
  4. Used to have a bottle of one of the older crosslink breakers. It was a failure in tests for lowering blood pressure but did a fantastic job cleaning your teeth; Decay bacteria rely on those same cross links to anchor themselves to teeth! A drop on the old tooth brush was as good as a professional cleaning.The life extension research really seems to be heating up. Actuarially I’ve got maybe another 20 years if I take care of myself. Some of this stuff might even be out of trials and available in time for me!

    Reply
  5. Used to have a bottle of one of the older crosslink breakers. It was a failure in tests for lowering blood pressure, but did a fantastic job cleaning your teeth; Decay bacteria rely on those same cross links to anchor themselves to teeth! A drop on the old tooth brush was as good as a professional cleaning.

    The life extension research really seems to be heating up. Actuarially, I’ve got maybe another 20 years if I take care of myself. Some of this stuff might even be out of trials and available in time for me!

    Reply
  6. Revel is the next company to be spun out (off Yale’s work on breaking glucosepane crosslinks). Should happen in the next few months. Will target high blood pressure due to inelastic arteries and wrinkles.

    Also in the past week Repair Biotechnologies Inc (founded by Reason, author of the Fightaging blog) has been funded by the Grapeseed Bio fund:

    “Founded by Reason and Bill Cherman in April 2018, Repair Biotechnologies will use these new funds to expand its foundational gene therapy development work with the addition of a recombinant protein engineering program, as it proceeds towards proof of concept results in animal models.”

    Repair Bio will use a FOXN1 gene therapy to attempt to rejuvenate the thymus, and probably an engineered bacterial enzyme to try and remove oxidised cholesterol from foam cells in the arteries.

    Reply

Leave a Comment